Print Page  Close Window

Investor Overview

Title
Download Documentation Investor Presentation September 2017
Get help downloading or viewing the above file types

Corporate Profile

Calithera Biosciences is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule oncology drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment.... More >>

Recent News

09/20/17
Calithera Biosciences to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference and the Leerink Partners Immuno-Oncology Roundtable
09/19/17
Calithera Biosciences Announces CB-839 in Combination with Nivolumab Phase 1/2 Data Accepted for Oral Presentation at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting
View More >>

In the Media

Download Documentation BioCentury- Triple Shot

Stock Quote

CALA (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$16.45
Change (%) Stock is Up 0.35 (2.17%)
Volume449,035
Data as of 09/20/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
CALA (Common Stock)
Stock chart for: CALA.OQ.  Currently trading at $16.45 with a 52 week high of $20.05 and a 52 week low of $2.20.

Upcoming Events

Wednesday, September 27, 2017 9:10 a.m. ET
Calithera Biosciences, Inc. at Cantor Fitzgerald Global Healthcare Conference

Thursday, September 28, 2017 8:30 a.m. ET
Calithera Biosciences, Inc. at the Leerink Partners Immuno-Oncology Roundtable

View More >>
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources